Health Effects of Repeated Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Volunteers

Repeated Exposure Study

Purpose: To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints in healthy young individuals.

Participants: 20 healthy males and females aged 18-35 years.

Procedures (methods): Subjects will be randomly exposed to three consecutive days of filtered air (4 hr/day) and three consecutive days of PM2.5 (approximately 35 µg/m3; 4 hr/day) in an exposure chamber. Blood collection for inflammatory factors such as C-reactive protein (CRP), clotting factors; heart rate variability (HRV); spirometry; and a symptom questionnaire will be conducted before and after each exposure.

Study Overview

• Status: Recruiting
• Conditions: Air Pollution
• Intervention / Treatment: Other: Filtered air exposure; Other: PM exposure

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Patrice Ratliffe; Phone Number: 919-966-0607; Email: Ratliffe.Patrice@epa.gov

Study Locations

• United States
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27514
      • Recruiting
      • EPA Human Studies Facility
      • Contact: Patrice Ratliffe; Phone Number: 919-966-0607; Email: Ratliffe.Patrice@epa.gov
      • Principal Investigator: Haiyan Tong, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. . Age 18-35 years old healthy male and female (BMI values between 19 and 30).
2. . Physical conditioning allowing intermittent, moderate exercise for 2 hours, and ability to complete the exposure exercise regimen to induce a minute ventilation rate of 20 L/min/m2 for 15 min without exceeding 80% of projected maximal heart rate. Predicted maximal heart rate will be calculated using the equation [described by Tanaka et al.: (2001) J. Am. Coll. Cardiol: 208bpm-((0.7) x (age in years))]
3. . Normal baseline 12-lead EKG.

4. . Normal lung function based on NHANES III reference values. i. Forced vital capacity (FVC) ≥ 80% of that predicted for age, gender, ethnicity, and height.

   ii. Forced expiratory volume in one second (FEV1) ≥ 80% of that predicted for age, gender, ethnicity, and height.

   iii: FEV1/FVC ratio ≥ 80% of predicted values.

5. . Oxygen saturation greater than 94% at the time of physical exam.

Exclusion Criteria:

1. . Individuals with a diagnosis of COVID-19 and/or hospitalized for COVID-19.
2. . Individuals not vaccinated for COVID-19, or, not 14 days beyond the final dose of receiving a COVID-19 vaccine.
3. . Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic diseases, or immunodeficiency state.
4. . Individuals with a CVD risk score greater than 10% using the ACC/AHA ASCVD risk calculator (based on the 10-year risk of heart disease or stroke using the Atherosclerotic Cardiovascular Disease algorithm published in 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular risk.
5. . Individuals with asthma and a history of asthma.
6. . Individuals who are allergic to chemical vapors or gases.
7. . Females who are pregnant, attempting to become pregnant, or breastfeeding.
8. . Individuals who are currently smoking (including vaping, hookah, e-cigarette) or have a smoking history within 1 year of study.
9. . Individuals living with a smoker who smokes inside the house.
10. . Individuals with a body mass index (BMI) >30 or <19. Body mass index is calculated by dividing the weight in kilograms by the square of the height in meters.
11. . Individuals with occupational exposures to high levels of vapors, dust, gases, or fumes on an on-going basis.
12. . Individuals with uncontrolled hypertension (>140 systolic or >90 diastolic).
13. . Individuals who do not understand or speak English.
14. . Individuals who are unable to perform the exercise required for the study.
15. . Individuals with a history of skin allergies to adhesives used in securing EKG electrodes.
16. . Individuals with unspecified diseases, conditions, or medications that might influence the responses to the exposures, as judged by the medical staff.
17. . Individuals who are unwilling or unable to stop taking over-the-counter pain medications such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), or other non-steroidal anti-inflammatory ("NSAID") medications for 48 hours prior to the exposures and post-exposure visits. Individuals taking vitamins or supplements that the investigators believe may impact the results of the study who are unwilling or unable to stop taking them for at least two weeks before the study. Those not specifically mentioned here may be reviewed by the investigators prior to an individual's inclusion in the study.
18. . Individuals taking systemic steroids or beta-blocker medications.
19. . Individuals with a hemoglobin A1c (HbA1c) level > 6.4%.
20. . Individuals who are claustrophobic.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Filtered air exposure; Subjects will be randomly exposed to three consecutive days of filtered air exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the PM2.5 arm.	Other: Filtered air exposure; To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
Experimental: PM exposure; Subjects will be randomly exposed to three consecutive days of PM2.5 exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the filtered air arm.	Other: PM exposure; To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood inflammation marker, CRP, will be measured 2 hours before each air exposure day and follow up day in 20 subjects	Venous blood will be collected for CRP measurement 2 hours before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.	Four days
Blood inflammation marker, CRP, will be measured 2 hours before each PM exposure day and follow up day in 20 subjects	Venous blood will be collected for CRP measurement 2 hours before each PM exposure day on day 1, day 2, day 3 and follow up day in 20 subjects.	Four days
Blood inflammation marker, CRP, will be measured 1 hour after each air exposure day in 20 subjects	Venous blood will be collected for CRP measurement 1 hour after each air exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days
Blood inflammation marker, CRP, will be measured 1 hour after each PM exposure day in 20 subjects	Venous blood will be collected for CRP measurement 1 hour after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Spirometry will be measured 1 hour before each air exposure day and follow up day in 20 subjects	FEV1 and FVC will be measured by spirometry 1 hour before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.	Four days
Spirometry will be measured 1 hour before each PM exposure day and follow up day in 20 subjects	FEV1 and FVC will be measured by spirometry 1 hour before each PM exposure day on day 1, day 2, day 3 and follow up day in 20 subjects.	Four days
Ambulatory ECG will be measured 2 hours before each air exposure day and follow up day in 20 subjects	ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hour before each air exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.	Four days
Ambulatory ECG will be measured 2 hours before each PM exposure day and follow up day in 20 subjects	ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours before each PM exposure day on day 1, day 2, day 3, and follow up day in 20 subjects.	Four days
Spirometry will be measured 1 hour after each air exposure day in 20 subjects	FEV1 and FVC will be measured by spirometry 1 hour after each air exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days
Spirometry will be measured 1 hour after each PM exposure day in 20 subjects	FEV1 and FVC will be measured by spirometry 1 hour after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days
Ambulatory ECG will be measured 2 hours after each air exposure day in 20 subjects	ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours after each air exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days
Ambulatory ECG will be measured 2 hours after each PM exposure day in 20 subjects	ECG QT interval and frequency power of ECG will be measured by Holter monitor for 5 minutes at 2 hours after each PM exposure day on day 1, day 2, and day 3 in 20 subjects.	Three days

Collaborators and Investigators

• Sponsor: U.S. EPA Human Studies Facility

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2022
• Primary Completion (Estimated): June 20, 2024
• Study Completion (Estimated): December 20, 2025

Study Registration Dates

• First Submitted: November 29, 2021
• First Submitted That Met QC Criteria: April 11, 2022
• First Posted (Actual): April 12, 2022

Study Record Updates

• Last Update Posted (Actual): November 28, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: RPTCAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No